Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
- PMID: 27457966
- PMCID: PMC5045517
- DOI: 10.1530/ERP-16-0020
Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy
Abstract
Background: Cardiotoxicity from anthracycline-based chemotherapy is an important cause of early and late morbidity and mortality in breast cancer patients. Left ventricular (LV) function is assessed for patients receiving anthracycline-based chemotherapy to identify cardiotoxicity. However, animal studies suggest that right ventricular (RV) function may be a more sensitive measure to detect LV dysfunction. The purpose of this pilot study was to determine if breast cancer patients undergoing anthracycline-based chemotherapy experience RV dysfunction.
Methods: Forty-nine breast cancer patients undergoing anthracycline-based chemotherapy at the Ottawa Hospital between November 2007 and March 2013 and who had 2 echocardiograms performed at least 3months apart were retrospectively identified. Right atrial area (RAA), right ventricular fractional area change (RV FAC) and RV longitudinal strain of the free wall (RV LSFW) were evaluated according to the American Society of Echocardiography guidelines.
Results: The majority (48/49) of patients were females with an average age of 53.4 (95% CI: 50.1-56.7years). From baseline to follow-up study, average LV ejection fraction (LVEF) decreased from 62.22 (95% CI: 59.1-65.4) to 57.4% (95% CI: 54.0-60.9) (P=0.04). During the same time period, the mean RAA increased from 12.1cm(2) (95% CI: 11.1-13.0cm(2)) to 13.8cm(2) (95% CI: 12.7-14.9cm(2)) (P=0.02), mean RV FAC decreased (P=0.01) from 48.3% (95% CI: 44.8-51.74) to 42.1% (95% CI: 38.5-45.6%), and mean RV LSFW worsened from -16.2% (95% CI: -18.1 to -14.4%) to -13.81% (95% CI: -15.1 to -12.5%) (P=0.04).
Conclusion: This study demonstrates that breast cancer patients receiving anthracycline-based chemotherapy experience adverse effects on both right atrial size and RV function. Further studies are required to determine the impact of these adverse effects on right heart function and whether this represents an earlier marker of cardiotoxicity.
Keywords: cardiotoxicity; chemotherapy; echocardiography; right heart function.
© 2016 The authors.
Figures
Similar articles
-
Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.BMC Cancer. 2018 Oct 25;18(1):1037. doi: 10.1186/s12885-018-4935-z. BMC Cancer. 2018. PMID: 30359235 Free PMC article.
-
Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy.J Oncol. 2015;2015:609194. doi: 10.1155/2015/609194. Epub 2015 Aug 3. J Oncol. 2015. PMID: 26339242 Free PMC article.
-
Early Detection and Prediction of Anthracycline-Induced Right Ventricular Cardiotoxicity by 3-Dimensional Echocardiography.JACC CardioOncol. 2020 Mar 17;2(1):13-22. doi: 10.1016/j.jaccao.2020.01.007. eCollection 2020 Mar. JACC CardioOncol. 2020. PMID: 34396205 Free PMC article.
-
Anthracycline-Induced Subclinical Right Ventricular Dysfunction in Breast Cancer Patients: A Systematic Review and Meta-Analysis.Cancers (Basel). 2024 Nov 20;16(22):3883. doi: 10.3390/cancers16223883. Cancers (Basel). 2024. PMID: 39594841 Free PMC article. Review.
-
Chemotherapy induced right ventricular cardiomyopathy; a systematic review and meta-analysis.Front Cardiovasc Med. 2023 Aug 3;10:1103941. doi: 10.3389/fcvm.2023.1103941. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37600030 Free PMC article. Review.
Cited by
-
Right ventricular free wall strain for detection of anthracycline induced cardiac toxicity.Int J Cardiovasc Imaging. 2022 May;38(5):1021-1028. doi: 10.1007/s10554-021-02446-2. Epub 2022 Mar 28. Int J Cardiovasc Imaging. 2022. PMID: 38819728
-
Effects of chemotherapy treatment with doxorubicin on right ventricular function in dogs.J Vet Med Sci. 2024 Aug 2;86(8):885-891. doi: 10.1292/jvms.24-0004. Epub 2024 Jul 3. J Vet Med Sci. 2024. PMID: 38960666 Free PMC article.
-
The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy.Int J Cardiovasc Imaging. 2019 Jun;35(6):1009-1017. doi: 10.1007/s10554-019-01590-0. Epub 2019 Apr 2. Int J Cardiovasc Imaging. 2019. PMID: 30941563
-
Daratumumab May Attenuate Cardiac Dysfunction Related to Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma: A Prospective Study.Cancers (Basel). 2021 Oct 9;13(20):5057. doi: 10.3390/cancers13205057. Cancers (Basel). 2021. PMID: 34680206 Free PMC article.
-
The influence of chemotherapy on the right ventricle: did we forget something?Clin Cardiol. 2017 Jul;40(7):437-443. doi: 10.1002/clc.22672. Epub 2017 Feb 13. Clin Cardiol. 2017. PMID: 28191909 Free PMC article. Review.
References
-
- Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, Hagerty KL, Somerfield MR, Vaughn DJ, for the ASCO Cancer Survivorship Expert Panel 2007. ASCO Cancer Survivorship Expert Panel. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. Journal of Clinical Oncology 25 3991–4008. (10.1200/JCO.2007.10.9777) - DOI - PubMed
-
- Oliveira GH, Dupont M, Naftel D, Myers SL, Yuan Y, Tang WH, Gonzalez-Stawinski G, Young JB, Taylor DO, Starling RC. 2014. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). Journal of the American College of Cardiology 63 240–248. (10.1016/j.jacc.2013.09.040) - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources